Surmodics traded at $37.60 this Wednesday July 6th, decreasing $0.87 or 2.26 percent since the previous trading session. Looking back, over the last four weeks, Surmodics lost 5.41 percent. Over the last 12 months, its price fell by 29.60 percent. Looking ahead, we forecast Surmodics to be priced at 36.80 by the end of this quarter and at 33.88 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 108.69 -0.61 -0.56% -9.33%
Align Technology 249.54 -4.57 -1.80% -59.24%
Anika Therapeutics 22.50 -0.25 -1.10% -48.07%
Arrowhead Research 39.99 0.83 2.12% -37.25%
Baxter International 65.11 -0.28 -0.43% -20.45%
BioScrip 28.39 -0.11 -0.39% 27.60%
Boston Scientific 37.66 -0.10 -0.26% -14.27%
Artivion Inc 19.33 -0.06 -0.31% -31.14%
EDAP TMS 6.55 0.05 0.77% 0.92%
Edwards Lifesciences 97.98 0.01 0.01% -9.18%
Haemonetics 65.58 -0.91 -1.37% 3.77%
Heron Therapeutics 3.14 0.14 4.67% -77.76%
J&J 178.30 0.16 0.09% 5.25%
Mesa Laboratories 201.66 -2.93 -1.43% -26.83%
Merit Medical Systems 53.36 -1.10 -2.02% -16.03%
Nektar Therapeutics 3.90 -0.03 -0.76% -76.53%
Surmodics 37.60 -0.87 -2.26% -29.60%
Stryker 200.76 -1.26 -0.62% -24.34%
Trinity Biotech 1.30 -0.08 -5.80% -49.22%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%

Surmodics
Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.